Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

计划入组 69 人 · 首次发布于 2019 年 7 月 16 日

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

计划入组 40 人 · 首次发布于 2017 年 6 月 7 日

Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor

计划入组 20 人 · 首次发布于 2015 年 10 月 27 日

huMNC2-CAR22 T cells

huMNC2-CAR22(Minerva Biotechnologies)

HSP-MUC1

MUC Research GmbH

Germany

Minerva Biotechnologies Advances MUC1*-Targeted CAR-T Therapy with 1XX Mutations for Solid Tumors

South African Scientists Decode How Cancer Rewires MUC1 Sugar Coating to Evade the Immune System

Hypoxia-Induced Gene Signature Drives Breast Cancer Metastasis: MUC1 as a Therapeutic Target